Login to Your Account



Biogen Idec Forms Parkinson's Deal With Vernalis For $100M

By Nuala Moran


Wednesday, June 30, 2004
LONDON - Vernalis plc landed a deal potentially worth $100 million with Biogen Idec Inc. for Vernalis' Parkinson's disease program that is in Phase I work. Biogen is paying an initial license fee of $10 million and investing $6 million in Vernalis, with a promise to invest a further $4 million in any future Vernalis fund raising. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription